Nexium News and Research

RSS
Esomeprazole is a proton pump inhibitor (brand names Sompraz, Zoleri, Nexium, Lucen, Esopral; Axagon in Italy, Nexiam in Belgium and South Africa) developed and marketed by AstraZeneca which is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the ''S''-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole. However, this greater efficacy has been disputed, with some claiming it offers no benefit from its older form.
Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

Save billions or stick with Humira? Drug brokers steer Americans to the costly choice

The drug company that prospered without creating any drugs

The drug company that prospered without creating any drugs

Common heart burn medication could lessen the effectiveness of lung cancer treatment

Common heart burn medication could lessen the effectiveness of lung cancer treatment

Investigational drug reduces heartburn severity in patients with refractory GERD

Investigational drug reduces heartburn severity in patients with refractory GERD

Study links use of acid reflux drugs with poorer concentration, memory in breast cancer survivors

Study links use of acid reflux drugs with poorer concentration, memory in breast cancer survivors

Gastroesophageal reflux disease may affect nearly a third of U.S. adults every week

Gastroesophageal reflux disease may affect nearly a third of U.S. adults every week

Popular heartburn drug voluntarily recalled for carcinogen levels above FDA standards

Popular heartburn drug voluntarily recalled for carcinogen levels above FDA standards

Potential side effects increase in children with use of common reflux aids, study shows

Potential side effects increase in children with use of common reflux aids, study shows

Study links heartburn drugs to fatal cases of heart, kidney disease and gastrointestinal cancer

Study links heartburn drugs to fatal cases of heart, kidney disease and gastrointestinal cancer

Common acid reflux drugs tied to elevated risk for kidney disease

Common acid reflux drugs tied to elevated risk for kidney disease

Invasive surgery should be done for select patients with acid reflux, says study

Invasive surgery should be done for select patients with acid reflux, says study

Common acid reflux drugs linked to progression of chronic liver disease

Common acid reflux drugs linked to progression of chronic liver disease

Proton pump inhibitors linked to increased death risk

Proton pump inhibitors linked to increased death risk

Longtime use of heartburn drugs linked to increased risk of death

Longtime use of heartburn drugs linked to increased risk of death

Former pharma reps’ new mission: To school docs on high drug costs

Former pharma reps’ new mission: To school docs on high drug costs

Prolonged use of popular heartburn drugs linked to silent, gradual kidney damage

Prolonged use of popular heartburn drugs linked to silent, gradual kidney damage

Common heartburn medications could decrease effects of chemotherapy in cancer patients

Common heartburn medications could decrease effects of chemotherapy in cancer patients

Chronic use of antacid drugs may speed up aging of blood vessels

Chronic use of antacid drugs may speed up aging of blood vessels

Acid suppression drugs frequently prescribed for high-risk newborns, study shows

Acid suppression drugs frequently prescribed for high-risk newborns, study shows

Camber Pharmaceuticals releases generic version of Nexium (Esomeprazole) capsules

Camber Pharmaceuticals releases generic version of Nexium (Esomeprazole) capsules

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.